Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination Influenza vaccination reduces the number of influenza virus infections but not the overall number of illness.
Trend scenario PHF- 2018 identifies societal challenges for the future If historical trends continue unchanged, dementia will be the leading cause of disease burden in 2040 and the main cause of death.
EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
Health effects due to titanium nanoparticles in food and toothpaste cannot be excluded Health effects due to exposure to titanium dioxide nanoparticles via food, food supplements and toothpaste cannot be excluded.
Moderate flu season Last winter season, the duration and severity of the influenza epidemic was moderate compared to previous years.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
Tool for risk assessment of nanomaterials in cosmetics Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Flu season in the winter of 2014 / 2015 more severe and longer than preceding years The flu epidemic in the winter of 2014 / 2015 lasted 21 weeks and as such was the longest epidemic ever recorded in the Netherlands. Nearly two million people suffered from flu-like symptoms.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.